Detalhe da pesquisa
1.
Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents.
Br J Haematol
; 204(3): 898-909, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37946611
2.
Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS.
NEJM Evid
; 1(10): EVIDoa2200034, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-38319837